Sugi Predict

Sugi Predict / Compounds / SCHEMBL16636823

SCHEMBL16636823

SCHEMBL16636823

CC(=O)c1cc(Cl)c(Br)cc1N

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC9A1 P19634 1/20 0.40
▸ GAA P10253 3/20 0.38
▸ AHR P35869 2/20 0.38
▸ MAOB P27338 2/20 0.37
▸ MAOA P21397 1/20 0.37
▸ ABL1 P00519 1/20 0.36
▸ MAPT P10636 4/20 0.36
▸ ALDH1A1 P00352 4/20 0.36
▸ PKM P14618 1/20 0.36
▸ POLB P06746 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CYP3A4 P08684 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30390446 1.00 SLC9A1 (0.40) SLC9A1GAAAHRMAOBMAOA
SCHEMBL30818918 0.84 SLC9A1 (0.44) SLC9A1GAAABL1MAPTALDH1A1
SCHEMBL4591470 0.84 SLC9A1 (0.44) SLC9A1GAAABL1MAPTALDH1A1
SCHEMBL30626196 0.82 KDM4E (0.50) SLC9A1GAAAHRMAPTALDH1A1
SCHEMBL7023673 0.82 KDM4E (0.50) SLC9A1GAAAHRMAPTALDH1A1
SCHEMBL30077664 0.82 KDM4E (0.50) SLC9A1GAAAHRMAPTALDH1A1
SCHEMBL16117986 0.82 SLC9A1 (0.44) SLC9A1GAAAHRABL1MAPT
SCHEMBL30490123 0.81 AHR (0.38) SLC9A1GAAAHRPOLBL3MBTL1
SCHEMBL25223342 0.80 SLC9A1 (0.37) SLC9A1GAAAHRABL1ALDH1A1
SCHEMBL18668513 0.80 GAA (0.57) GAAABL1MAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KHORA SPV 1 LLC (US) 2025-10-30 — — US disclosed
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases KHORA SPV 1, LLC (US) 2025-06-17 — — US disclosed
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20180118757-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2018-05-03 — — US disclosed
US-9840516-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2017-12-12 — — US disclosed
US-9840516-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2017-12-12 — — US disclosed
US-9840516-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2017-12-12 — — US disclosed
EP-3055290-A1 INHIBITORS OF KRAS G12C Araxes Pharma LLC (US) 2016-08-17 — — EP disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS SLC9A1 2464/4885GAA 3549/4885AHR 2040/4885
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 SLC9A1 4628/4885GAA 427/4885AHR 1535/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS SLC9A1 1931/4885GAA 2356/4885AHR 2688/4885
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 SLC9A1 4628/4885GAA 427/4885AHR 1535/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC9A1 1931/4885GAA 2356/4885AHR 2688/4885
US-20180118757-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC9A1 1931/4885GAA 2356/4885AHR 2688/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC9A1 1694/4885GAA 2064/4885AHR 2477/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC9A1 1694/4885GAA 2064/4885AHR 2477/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC9A1 1694/4885GAA 2064/4885AHR 2477/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC9A1 1694/4885GAA 2064/4885AHR 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.